**Core Concept**
In chronic congestive cardiac failure, the primary goal of pharmacotherapy is to reduce mortality and morbidity by improving cardiac function and symptoms. This is often achieved through the use of evidence-based therapies that target the underlying pathophysiology of heart failure.

**Why the Correct Answer is Right**
The correct answer is **Metoprolol** (Option C). Metoprolol is a beta-blocker that is commonly used in the management of heart failure. Beta-blockers like metoprolol work by reducing the sympathetic nervous system's stimulation of the heart, thereby decreasing heart rate, blood pressure, and cardiac workload. This leads to improved cardiac function, reduced morbidity, and ultimately, prolonged survival in patients with chronic congestive cardiac failure.

**Why Each Wrong Option is Incorrect**
**Option A:** **Digoxin** is a cardiac glycoside that is used to improve symptoms of heart failure, but it does not have a significant impact on mortality.
**Option B:** **Hydralazine** is a vasodilator that is often used in combination with nitrates to reduce afterload and improve symptoms in patients with heart failure. It has been shown to reduce mortality in certain populations.
**Option D:** **Spironolactone** is an aldosterone antagonist that has been shown to reduce mortality in patients with severe heart failure. It works by blocking the effects of aldosterone, which leads to reduced fibrosis and improved cardiac function.

**Clinical Pearl / High-Yield Fact**
In patients with heart failure, beta-blockers like metoprolol should be initiated at low doses and gradually increased to achieve the desired effect. This is because sudden withdrawal of beta-blockers can lead to rebound hypertension and worsening heart failure.

**Correct Answer:** C. Metoprolol